TGA issues product defect correction


Pharmacists are advised that Janssen is undertaking a product defect correction for one batch of Jurnista (hydromorphone hydrochloride) prolonged-release blister packs Janssen, following consultation with the TGA, is undertaking a product defect correction for one batch of Jurnista (hydromorphone hydrochloride) prolonged-release blister packs (8 mg, 14 tablets) due to potential damage to the tablets. A misalignment issue with

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Don't listen to only pharmacists on 7CPA
Next Pollies back pharmacists in harm minimisation